Literature DB >> 31665373

Spread of Antigenically Drifted Influenza A(H3N2) Viruses and Vaccine Effectiveness in the United States During the 2018-2019 Season.

Brendan Flannery1, Rebecca J Garten Kondor1, Jessie R Chung1, Manjusha Gaglani2, Michael Reis2, Richard K Zimmerman3, Mary Patricia Nowalk3, Michael L Jackson4, Lisa A Jackson4, Arnold S Monto5, Emily T Martin5, Edward A Belongia6, Huong Q McLean6, Sara S Kim7, Lenee Blanton1, Krista Kniss1, Alicia P Budd1, Lynnette Brammer1, Thomas J Stark1, John R Barnes1, David E Wentworth1, Alicia M Fry1, Manish Patel1.   

Abstract

BACKGROUND: Increased illness due to antigenically drifted A(H3N2) clade 3C.3a influenza viruses prompted concerns about vaccine effectiveness (VE) and vaccine strain selection. We used US virologic surveillance and US Influenza Vaccine Effectiveness (Flu VE) Network data to evaluate consequences of this clade.
METHODS: Distribution of influenza viruses was described using virologic surveillance data. The Flu VE Network enrolled ambulatory care patients aged ≥6 months with acute respiratory illness at 5 sites. Respiratory specimens were tested for influenza by means of reverse-transcriptase polymerase chain reaction and were sequenced. Using a test-negative design, we estimated VE, comparing the odds of influenza among vaccinated versus unvaccinated participants.
RESULTS: During the 2018-2019 influenza season, A(H3N2) clade 3C.3a viruses caused an increasing proportion of influenza cases. Among 2763 Flu VE Network case patients, 1325 (48%) were infected with A(H1N1)pdm09 and 1350 (49%) with A(H3N2); clade 3C.3a accounted for 977 (93%) of 1054 sequenced A(H3N2) viruses. VE was 44% (95% confidence interval, 37%-51%) against A(H1N1)pdm09 and 9% (-4% to 20%) against A(H3N2); VE was 5% (-10% to 19%) against A(H3N2) clade 3C.3a viruses.
CONCLUSIONS: The predominance of A(H3N2) clade 3C.3a viruses during the latter part of the 2018-2019 season was associated with decreased VE, supporting the A(H3N2) vaccine component update for 2019-2020 northern hemisphere influenza vaccines. Published by Oxford University Press for the Infectious Diseases Society of America 2019.

Entities:  

Keywords:  influenza; influenza vaccine; vaccine effectiveness

Mesh:

Substances:

Year:  2020        PMID: 31665373      PMCID: PMC7325528          DOI: 10.1093/infdis/jiz543

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Improving Influenza Vaccine Effectiveness: Ways to Begin Solving the Problem.

Authors:  Arnold S Monto; Joshua G Petrie
Journal:  Clin Infect Dis       Date:  2019-10-30       Impact factor: 9.079

2.  Recommended composition of influenza virus vaccines for use in the 2018–2019 northern hemisphere influenza season.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2018-03-23

Review 3.  Serologic assays for influenza surveillance, diagnosis and vaccine evaluation.

Authors:  Jacqueline M Katz; Kathy Hancock; Xiyan Xu
Journal:  Expert Rev Anti Infect Ther       Date:  2011-06       Impact factor: 5.091

4.  Influenza Vaccine Effectiveness in the United States during the 2015-2016 Season.

Authors:  Michael L Jackson; Jessie R Chung; Lisa A Jackson; C Hallie Phillips; Joyce Benoit; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard Zimmerman; Mary P Nowalk; Alicia M Fry; Brendan Flannery
Journal:  N Engl J Med       Date:  2017-08-10       Impact factor: 91.245

5.  Recommended composition of influenza virus vaccines for use in the 2015–2016 northern hemisphere influenza season.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2015-03-13

6.  The test-negative design for estimating influenza vaccine effectiveness.

Authors:  Michael L Jackson; Jennifer C Nelson
Journal:  Vaccine       Date:  2013-03-13       Impact factor: 3.641

7.  Recommended composition of influenza virus vaccines for use in the 2015 southern hemisphere influenza season.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2014-10-10

8.  Effects of Influenza Vaccination in the United States During the 2017-2018 Influenza Season.

Authors:  Melissa A Rolfes; Brendan Flannery; Jessie R Chung; Alissa O'Halloran; Shikha Garg; Edward A Belongia; Manjusha Gaglani; Richard K Zimmerman; Michael L Jackson; Arnold S Monto; Nisha B Alden; Evan Anderson; Nancy M Bennett; Laurie Billing; Seth Eckel; Pam Daily Kirley; Ruth Lynfield; Maya L Monroe; Melanie Spencer; Nancy Spina; H Keipp Talbot; Ann Thomas; Salina M Torres; Kimberly Yousey-Hindes; James A Singleton; Manish Patel; Carrie Reed; Alicia M Fry
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 20.999

9.  Update: Influenza Activity in the United States During the 2018-19 Season and Composition of the 2019-20 Influenza Vaccine.

Authors:  Xiyan Xu; Lenee Blanton; Anwar Isa Abd Elal; Noreen Alabi; John Barnes; Matthew Biggerstaff; Lynnette Brammer; Alicia P Budd; Erin Burns; Charisse N Cummings; Shikha Garg; Rebecca Kondor; Larisa Gubareva; Krista Kniss; Sankan Nyanseor; Alissa O'Halloran; Melissa Rolfes; Wendy Sessions; Vivien G Dugan; Alicia M Fry; David E Wentworth; James Stevens; Daniel Jernigan
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-06-21       Impact factor: 17.586

10.  Influenza Vaccine Effectiveness in the United States During the 2016-2017 Season.

Authors:  Brendan Flannery; Jessie R Chung; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Melissa A Rolfes; Sarah Spencer; Alicia M Fry
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 20.999

View more
  49 in total

1.  Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination.

Authors:  Feng Liu; F Liaini Gross; Stacie N Jefferson; Crystal Holiday; Yaohui Bai; Li Wang; Bin Zhou; Min Z Levine
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

2.  A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.

Authors:  Raffael Nachbagauer; Jodi Feser; Abdollah Naficy; David I Bernstein; Jeffrey Guptill; Emmanuel B Walter; Franceso Berlanda-Scorza; Daniel Stadlbauer; Patrick C Wilson; Teresa Aydillo; Mohammad Amin Behzadi; Disha Bhavsar; Carly Bliss; Christina Capuano; Juan Manuel Carreño; Veronika Chromikova; Carine Claeys; Lynda Coughlan; Alec W Freyn; Christopher Gast; Andres Javier; Kaijun Jiang; Chiara Mariottini; Meagan McMahon; Monica McNeal; Alicia Solórzano; Shirin Strohmeier; Weina Sun; Marie Van der Wielen; Bruce L Innis; Adolfo García-Sastre; Peter Palese; Florian Krammer
Journal:  Nat Med       Date:  2020-12-07       Impact factor: 53.440

3.  Influence function methods to assess the effectiveness of influenza vaccine with survey data.

Authors:  Mingmei Tian; Jihnhee Yu; Denise F Lillvis; Albert Vexler
Journal:  Health Serv Res       Date:  2021-10-22       Impact factor: 3.402

4.  Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model.

Authors:  Zach Menne; Vasilis C Pliasas; Richard W Compans; Sheniqua Glover; Constantinos S Kyriakis; Ioanna Skountzou
Journal:  Virology       Date:  2021-08-05       Impact factor: 3.513

5.  Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada.

Authors:  Shinhye Kim; Erica Sy Chuang; Suzana Sabaiduc; Romy Olsha; Samantha E Kaweski; Nathan Zelyas; Jonathan B Gubbay; Agatha N Jassem; Hugues Charest; Gaston De Serres; James A Dickinson; Danuta M Skowronski
Journal:  Euro Surveill       Date:  2022-09

6.  Influenza Vaccine Effectiveness for Prevention of Severe Influenza-Associated Illness Among Adults in the United States, 2019-2020: A Test-Negative Study.

Authors:  Carlos G Grijalva; Leora R Feldstein; H Keipp Talbot; Michael Aboodi; Adrienne H Baughman; Samuel M Brown; Jonathan D Casey; Heidi L Erickson; Matthew C Exline; D Clark Files; Kevin W Gibbs; Adit A Ginde; Michelle N Gong; Natasha Halasa; Akram Khan; Christopher J Lindsell; Samuel K Nwosu; Ithan D Peltan; Matthew E Prekker; Todd W Rice; Nathan I Shapiro; Jay S Steingrub; William B Stubblefield; Mark W Tenforde; Manish M Patel; Wesley H Self
Journal:  Clin Infect Dis       Date:  2021-10-20       Impact factor: 9.079

7.  Vaccine Effectiveness Against Influenza-Associated Hospitalizations Among Adults, 2018-2019, US Hospitalized Adult Influenza Vaccine Effectiveness Network.

Authors:  Jill M Ferdinands; Manjusha Gaglani; Shekhar Ghamande; Emily T Martin; Donald Middleton; Arnold S Monto; Fernanda Silveira; Helen K Talbot; Richard Zimmerman; Emily R Smith; Manish Patel
Journal:  J Infect Dis       Date:  2021-07-02       Impact factor: 5.226

8.  Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States.

Authors:  Jessie R Chung; Brendan Flannery; Sara S Kim; Manjusha Gaglani; Chandni Raiyani; Edward A Belongia; Huong Q McLean; Mary Patricia Nowalk; Richard K Zimmerman; Michael L Jackson; Lisa A Jackson; Emily T Martin; Arnold S Monto; Manish Patel
Journal:  Vaccine       Date:  2021-05-13       Impact factor: 4.169

9.  Nanopore metagenomic sequencing of influenza virus directly from respiratory samples: diagnosis, drug resistance and nosocomial transmission, United Kingdom, 2018/19 influenza season.

Authors:  Yifei Xu; Kuiama Lewandowski; Louise O Downs; James Kavanagh; Thomas Hender; Sheila Lumley; Katie Jeffery; Dona Foster; Nicholas D Sanderson; Ali Vaughan; Marcus Morgan; Richard Vipond; Miles Carroll; Timothy Peto; Derrick Crook; A Sarah Walker; Philippa C Matthews; Steven T Pullan
Journal:  Euro Surveill       Date:  2021-07

10.  Effects of Influenza Vaccination in the United States During the 2018-2019 Influenza Season.

Authors:  Jessie R Chung; Melissa A Rolfes; Brendan Flannery; Pragati Prasad; Alissa O'Halloran; Shikha Garg; Alicia M Fry; James A Singleton; Manish Patel; Carrie Reed
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 20.999

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.